Skip to main content

Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach

Buy Article:

$51.00 plus tax (Refund Policy)



Gastrointestinal stromal tumour is now recognized as a distinct pathological malignancy and has received much attention over the last few years. Despite almost universal resistance to chemotherapy, a novel therapy, Imatinib, which targets the KIT receptor, has changed the natural history of this disease. We have audited the first 26 consecutive patients with gastrointestinal stromal tumour treated over 4 years at a single institution. A practical guide to the management of common toxicities and drug resistance is reported with a review of the published reports. Many of the strategies used are likely to be widely applicable to the use of targeted therapies in other malignancies.

Keywords: Imatinib; gastrointestinal stromal tumour; metastatic cancer; surgery; toxicity

Document Type: Research Article


Affiliations: Department of Medical Oncology, Prince of Wales Hospital

Publication date: June 1, 2006

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more